**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A compound comprising the formula:




,

or a pharmacologically acceptable addition salt thereof,

wherein $\mathbf{R_1}$ and $\mathbf{R_2}$ are independently selected from the group consisting of:

a) hydrogen;

b) alkyl, alkenyl of not less than 3 carbons, or alkynyl of not less than 3 carbons; wherein said alkyl, alkenyl, or alkynyl is either unsubstituted or substituted with one or more substituents selected from the group consisting of hydroxy, alkoxy, amino, alkylamino, dialkylamino, heterocyclyl, acylamino, alkylsulfonylamino, and heterocyclylcarbonylamino; and

c) aryl or ~~substituted~~ aryl substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, amino, nitro, carboxy, carbalkoxy, cyano,

alkylamino, dialkylamino, halo, hydroxy, hydroxyalkyl, mercaptyl, alkylmercaptyl, trihaloalkyl, carboxyalkyl, sulfoxy, and carbamoyl;

$\mathbf{R_3}$ is selected from the group consisting of:

(a) a bicyclic, tricyclic or pentacyclic group selected from the group consisting of:





wherein the bicyclic or tricyclic group is either unsubstituted or substituted with one or more substitents selected from the group consisting of:

~~(a) alkyl, alkenyl, and alkynyl substituted with one or more $R_5$-alkylamino substituents; and~~

~~(b~~ oxo, $R_5$-alkylsulfonylamino, and $R_5$-alkylthio~~, and phosphono,~~; and

(b) the tricyclic group:



wherein the tricyclic group is substituted with one or more substituents selected from the group consisting of:

(a) alkyl, alkenyl, and alkynyl; wherein each alkyl, alkenyl, or alkynyl group is either unsubstituted or substituted with one or more substituents selected from the group consisting of (amino)($R_5$)acylhydrazinylcarbonyl, (amino)($R_5$)acyloxycarboxy, (hydroxy)(carboalkoxy)alkylcarbamoyl, acyloxy, aldehydo, alkenylsulfonylamino, alkoxy, alkoxycarbonyl, alkylaminoalkylamino, alkylphosphono, alkylsulfonylamino, carbamoyl, $R_5$, $R_5$-alkoxy, ~~$R_5$-alkylamino,~~ cyano, cyanoalkylcarbamoyl, cycloalkylamino, dialkylamino, dialkylaminoalkylamino, dialkylphosphono, haloalkylsulfonylamino, ~~heterocyclylalkylamino~~ (heterocyclylalkyl)amino, heterocyclylcarbamoyl, hydroxy, hydroxyalkylsulfonylamino, oximino, ~~phosphono,~~ substituted aralkylamino, substituted arylcarboxyalkoxycarbonyl, substituted heteroarylsulfonylamino, substituted heterocyclyl, thiocarbamoyl, and trifluoromethyl; and

(b) (alkoxycarbonyl)aralkylcarbamoyl, aldehydo, alkenoxy, alkenylsulfonylamino, alkoxy, alkoxycarbonyl, alkylcarbamoyl, alkoxycarbonylamino, alkylsulfonylamino, alkylsulfonyloxy, amino, aminoalkylaralkylcarbamoyl, aminoalkylcarbamoyl, aminoalkylheterocyclylalkylcarbamoyl, aminocycloalkylalkylcycloalkylcarbamoyl, aminocycloalkylcarbamoyl, aralkoxycarbonylamino, arylheterocyclyl, aryloxy, arylsulfonylamino, arylsulfonyloxy, carbamoyl, oxo, -$R_5$, $R_5$-alkoxy, $R_5$-alkyl(alkyl)amino, $R_5$-alkylalkylcarbamoyl, ~~$R_5$-alkylamino~~, $R_5$-alkylcarbamoyl, $R_5$-alkylsulfonyl, $R_5$-alkylsulfonylamino, $R_5$-alkylthio, $R_5$-heterocyclylcarbonyl, cyano, cycloalkylamino, dialkylaminoalkylcarbamoyl, halogen, heterocyclyl, ~~heterocyclylalkylamino~~ (heterocyclylalkyl)amino, oximino, ~~phosphono,~~

substituted aralkylamino, substituted heterocyclyl, substituted heterocyclylsulfonylamino, ~~sulfoxyacylamino~~ (sulfoxyacyl)amino, and thiocarbamoyl;

**$R_4$** is selected from the group consisting of hydrogen, $C_{1-4}$-alkyl, $C_{1-4}$-alkyl-$CO_2H$, and phenyl, wherein the $C_{1-4}$-alkyl, $C_{1-4}$-alkyl-$CO_2H$, and phenyl groups are either unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, -OH, -OMe, $-NH_2$, $NO_2$, benzyl, and benzyl substituted with one to three substituents selected from the group consisting of halogen, -OH, -OMe, $-NH_2$, and $-NO_2$;

**$R_5$** is selected from the group consisting of $-CH_2COOH$, $-C(CF_3)_2OH$, $-CONHNHSO_2CF_3$, $-CONHOR_4$, $-CONHSO_2R_4$, $-CONHSO_2NHR_4$, $-C(OH)R_4PO_3H_2$, $-NHCOCF_3$, $-NHCONHSO_2R_4$, $-NHPO_3H_2$, $-NHSO_2R_4$, $-NHSO_2NHCOR_4$, $-OPO_3H_2$, $-OSO_3H$, $-PO(OH)R_4$, $-PO_3H_2$, $-SO_3H$, $-SO_2NHR_4$, ~~$-SO_3NHCOR_4$~~ $-OSO_2NHCOR_4$, ~~$-SO_3NHCONHCO_2R_4$~~ $-OSO_2NHCONHCO_2R_4$, and the following:



;

**$X_1$** and **$X_2$** are independently selected from the group consisting of O and S;

**Z** is selected from the group consisting of a single bond, -O-, $-(CH_2)_{1-3}-$, $-O(CH_2)_{1-2}-$, $-CH_2OCH_2-$, $-(CH_2)_{1-2}O-$, $-CH=CHCH_2-$, $-CH=CH-$, and $-CH_2CH=CH-$; and

$\mathbf{R_6}$ is selected from the group consisting of hydrogen, alkyl, acyl, alkylsulfonyl, aralkyl, substituted aralkyl, substituted alkyl, and heterocyclyl.

2. (Original) The compound of claim 1, wherein the compound is in a form selected from the group consisting of an achiral compound, a racemate, an optically active compound, a pure diastereomer, a mixture of diastereomers, and a pharmacologically acceptable addition salt.

3. (Original) The compound of claim 1, wherein $\mathbf{R_1}$ and $\mathbf{R_2}$ are each alkyl groups.

4. (Original) The compound of claim 1, wherein $\mathbf{R_1}$ and $\mathbf{R_2}$ are each n-propyl.

5. (Previously presented) The compound of claim 1, wherein $\mathbf{R_1}$ is n-propyl and $\mathbf{R_6}$ is selected from the group consisting of an unsubstituted aralkyl; aralkyl substituted with -OH, -OMe, or -halogen; methyl; and 3-hydroxypropyl.

6. (Original) The compound of claim 4, wherein **Z** is a single bond.

7 – 10. (Canceled).

11. (Currently amended) The compound of claim 6, wherein $\mathbf{R_3}$ is



[ [ , ] ]

~~and wherein $R_3$ is either unsubstituted or substituted with one or more phosphono substituents~~.

12 – 38. (Canceled).

39. (Original) A medicament composition comprising a compound of claim 1 together with a suitable excipient.

40. (Canceled).

41. (Currently amended) A method of treating a subject suffering from a disease ~~The method of claim 40, wherein the condition is~~ selected from the group consisting of ~~cardiac and circulatory disorders, degenerative disorders of the central nervous system,~~ respiratory disorders, diseases for which diuretic treatment is indicated, ~~Parkinson's disease,~~ depression, traumatic brain damage, ~~post-stroke neurological deficit,~~ respiratory depression, neonatal brain trauma, ~~dyslexia, hyperactivity, cystic fibrosis,~~ cirrhotic ascites, neonatal apnea, renal failure, diabetes, and asthma~~, and edematous conditions~~.

42. (Currently amended) A method of treating a subject suffering from a disease ~~The method of claim 40~~, wherein the condition is congestive heart failure ~~or renal dysfunction~~.

43. (Canceled).